Feroscan

company

About

Development of 1st-in-class personalized organometallic with a unique & innovative mode of action coupled with nanoparticle

  • 1 - 10

Details

Last Funding Type
Seed
Last Funding Money Raised
€353K
Industries
Biotechnology,Health Care,Pharmaceutical
Founded date
Nov 7, 2014
Number Of Employee
1 - 10
Operating Status
Active

Feroscan was set up in 2014 at the initiative of its four founders bringing together scientific and business skills. Feroscan specializes in the development of first-in-class personalized cytotoxics with a unique and innovative mode of action. The pipeline of the company focuses on intractable cancers; such as ovarian, triple negative breast and NSCL cancers.
Feroscan’s business strategy is to test in parallel several preclinical programs on several orphan applications up to proof of concept, IND and early clinical stages. Feroscan is based on a strong IP strategy, cutting edge science and relies on a strong academic and industrial network worldwide to develop clinical applications of its research programs.

Funding Rounds

Number of Funding Rounds
Total Funding Amount
3
€0.95M
Feroscan has raised a total of €0.95M in funding over 2 rounds. Their latest funding was raised on Jul 11, 2019 from a Grant round.
Announced Date Round Money Raised Number of Investors Lead Investors Post Valuation
Jul 11, 2019 Grant €480K 1 Detail
Jul 13, 2018 Seed €353K 1 Groupe Azeden Detail
Jun 1, 2015 Grant €120K 1 Detail

Investors

Number of Lead Investors
Number of Investors
1
3
Feroscan is funded by 3 investors. Groupe Azeden and Agence National de la Recherche are the most recent investors.
Investor Name Lead Investor Funding Round
Groupe Azeden Yes Seed
Agence National de la Recherche Grant
Paris Sciences et Lettres Grant